
Bayer and CureVac to collaborate on COVID-19 vaccine candidate
pharmafile | January 8, 2021 | News story | Medical Communications | Bayer, COVID-19, Vaccine
Bayer is joining forces with CureVac, a biopharmaceutical company developing medicines based on messenger ribonucleic acid (mRNA), on its COVID-19 vaccine candidate CVnCoV.
Under the parties’ collaboration and services agreement, Bayer will support the further development, supply, and key territory operations of CureVac´s coronavirus jab.
CureVac commenced Phase IIb/III trials for its vaccine candidate last month, after ramping up its European manufacturing network in November.
CureVac will be the Marketing Authorisation Holder for the product. Bayer will support CureVac with country operations within the EU and selected additional markets, but holds further options to become Marketing Authorisation Holder in other markets outside of Europe.
The companies plan to supply hundreds of millions of CVnCoV doses globally once approvals are granted.
Stefan Oelrich, Member of the Board of Management at Bayer and President of the Bayer’s Pharmaceuticals Division, said: “The need for vaccines against COVID-19 is enormous. We are therefore pleased to be able to provide significant support to CureVac, a leader in mRNA technology, in advancing the further development and supply of its COVID-19 vaccine candidate.
“We are highly committed to making our capabilities and networks available to help end this pandemic.”
Darcy Jimenez
Related Content

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

Canada awards CSL Seqirus with influenza pandemic vaccine contract
CSL Seqirus has been awarded a contract committing it to manufacturing and delivering influenza vaccines …

Evotec and Bayer announce new kidney disease study
Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney …






